Dr. Randall E. Morris, MD, FRCP
Research Professor of Cardiothoracic Surgery and, by courtesy, Surgery and Medicine (Emeritus).
Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, California, USA
Dr. Morris was the founder and Director of the Laboratory for Transplantation Immunology, Stanford University School of Medicine and subsequently was recruited to become the Global Head of Transplantation Discovery Research & Head of Transplantation Translational Medicine in the Novartis Institutes of BioMedical Research, Basel, Switzerland.
Dr. Morris, with his teams and collaborators, were the first to discover new uses for, to patent, and/or to publish on 4 1st-in-class drugs for: 1) prevention and treatment of acute and chronic organ transplant rejection, 2) prevention of acute GvHD, 3) prevention of arterial restenosis after balloon angioplasty injury (Dr. Morris is the co-inventor of the 1st patent for the drug class [mTOR inhibitor] used in the most commonly implanted drug-eluting stents), and/or to publish on 4) the novel molecular mechanisms of action of these drugs: Sirolimus (mTOR inhibitor), Mycophenolate mofetil (IMPDH inhibitor), Tofacitinib (JAK inhibitor]) Efalizumab (anti-CD11a monoclonal antibody). Approximately 25 million patients have been treated with drugs in these classes after drug marketing approvals world-wide for 9 indications generating aggregated cumulative sales of approximately $80 billion for on- and off-label uses.
Dr. Morris has received no royalty income from sales of these drugs.